Continuing to Serve Customers and Deliver High-Quality Therapies to Patients Without Interruption; Vendors and Suppliers to be Paid in Full in the Ordinary Course DUBLIN, Aug. 30, 2023 /PRNewswire/ -- Mallinckrodt plc (OTC:MNKTQ) ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, today announced that it has received approvals from the U.S. Bankruptcy Court for the District of Delaware for its "First Day" motions related to the Company's voluntary Chapter 11 petitions filed on August 28, 2023. As expected, the Court granted Mallinckrodt approval to ac

Initiates Voluntary Prepackaged Chapter 11 Proceedings with Overwhelming Support of Key Stakeholders, Including 85%+ of First and Second Lien Debtholders Continuing to Operate Normally, Serve Customers and Deliver High-Quality Therapies to Patients Vendors and Suppliers Expected to be Paid in Full in the Ordinary Course DUBLIN, Aug. 28, 2023 /PRNewswire/ -- Mallinckrodt plc (NYSE:MNK) ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, today announced that it has taken the next step to implement the comprehensive financial restructuring plan contemplated by a Restructuring Support Agreement ("RSA") the Company previously entered into with more than 85% of each of th

Agreement Supported by a Substantial Majority of Each of its First and Second Lien Debtholders and Opioid Trust Financial Restructuring Plan to Significantly Reduce Debt, Increase Free Cash Flow Generation, Extend Maturity Runway and Better Position Company for Long-Term Success  Intends to Initiate Voluntary Prepackaged Chapter 11 Proceedings to Implement Plan Continuing to Deliver High-Quality Therapies to Patients and Serve Customers; Vendors and Suppliers to be Paid in Full in the Ordinary Course DUBLIN, Aug. 23, 2023 /PRNewswire/ -- Mallinckrodt plc (NYSE:MNK) ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, today announced it has entered into a Restructur

The Buxton Helmsley Group, Inc. (together with certain of its affiliates, "BHG" or "we"), the New York City-based investment advisor to clients with financial interests in Mallinckrodt Plc. ("Mallinckrodt" or the "Company") (NYSE:MNK), today issued an open letter (the "Letter") to the Company's Board of Directors, regarding the Company's continued failure to make required write-downs of asset values where expenses are evidenced, in apparent violation of GAAP ASC 350/360 and Regulation S-X, within its August 9, 2023, Form 10-Q filing with the U.S. Securities and Exchange Commission (the "Commission"). On March 17, 2023, BHG had issued a public report to the Company's Board of Directors (al

Reports Second Quarter Net Sales of $475.0 Million, Reflecting a 1.3% Growth on a Reported and Constant Currency Basis Compared to the Prior Year Quarter Reports Net Loss of $747.8 Million; Adjusted EBITDA of $144.0 Million; Cash on Hand of $480.6 Million at Second Quarter End Reaffirms 2023 Net Sales and Adjusted EBITDA Guidance Terlivaz® Launch Exceeds Expectations, Obtaining Approximately 50% of Targeted Hospital Formulary Access With Continued Medical Community Interest Provides Update on Liquidity and Discussions With Creditors and Opioid Disbursement Trust DUBLIN, Aug. 9, 2023 /PRNewswire/ -- Mallinckrodt plc (NYSE:MNK) ("Mallinckrodt" or the "Company"), a global specialty pharmaceutic

Investors can contact the law firm at no cost to learn more about recovering their losses ​LOS ANGELES, July 13, 2023 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Mallinckrodt plc ("Mallinckrodt" or the "Company") (NYSEAM:MNK) investors that a lawsuit filed on behalf of investors that purchased Mallinckrodt securities between June 17, 2022 and June 14, 2023, both dates inclusive (the "Class Period"). Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss invest

– Two scientific poster presentations at EASL 2023 will detail findings of Mallinckrodt's latest research providing insight into the therapeutic effect of TERLIVAZ® from baseline, and the clinical management of adults with HRS with rapid reduction in kidney function1 – DUBLIN, June 15, 2023 /PRNewswire/ -- Mallinckrodt plc (NYSE:MNK), a global specialty pharmaceutical company, today announced that two scientific posters detailing Mallinckrodt's latest research findings on the clinical outcomes of treatment with TERLIVAZ® (terlipressin) for injection and clinical management criteria for adult patients with hepatorenal syndrome (HRS) will be presented at the European Association for the Study

– Findings from two clinical studies in adults with HRS involving rapid reduction in kidney function1 provide insight into the use of terlipressin among patients with comorbidities and varying baseline characteristics2,3 – DUBLIN, June 1, 2023 /PRNewswire/ -- Mallinckrodt plc (NYSE:MNK), a global specialty pharmaceutical company, today announced the presentation of results from two clinical studies in adults with hepatorenal syndrome (HRS) with rapid reduction in kidney function1 treated with TERLIVAZ® (terlipressin) for injection at the American Transplant Congress (ATC) 2023, taking place in San Diego, Calif. from June 3-7, 2023. The results of the two studies – a pooled analysis of two Ph

The Buxton Helmsley Group, Inc. (together with certain of its affiliates, "BHG" or "we"), the New York City-based investment advisor to clients with financial interests in Mallinckrodt Plc. ("Mallinckrodt" or the "Company") (NYSE:MNK), today issued an open letter (the "Letter") to the Company's Board of Directors, given the Company's continued failure to make required write-downs of asset values where expenses are evidenced, in apparent violation of GAAP ASC 350/360 and Regulation S-X, within its May 9, 2023, Form 10-Q filing with the U.S. Securities and Exchange Commission (the "Commission"). On March 17, 2023, BHG issued a public report to the Company's Board of Directors (also delivere

Advanced Launch of Terlivaz® with Rapid and Successful Uptake in Hospital Formulary Access and Continued Medical Community Interest Reports First Quarter Net Sales of $424.6 Million; Net Loss of $249.3 Million; Adjusted EBITDA of $123.5 Million; Diluted Loss Per Share of $18.93 and Adjusted Diluted Earnings Per Share of $1.68 Increased Cash on Hand to $480.0 Million and Reduced Exposure to Interest Rate Volatility Through Interest Rate Cap Agreement, Demonstrating Ongoing Focus on Disciplined Balance Sheet Management Reaffirmed 2023 Net Sales and Adjusted EBITDA Guidance Conference Call and Webcast Today at 8:30 a.m. ET DUBLIN, May 9, 2023 /PRNewswire/ -- Mallinckrodt plc (NYSE:MNK) ("Malli

4 - Mallinckrodt plc (0001567892) (Issuer)

4 - Mallinckrodt plc (0001567892) (Issuer)

4 - Mallinckrodt plc (0001567892) (Issuer)

4 - Mallinckrodt plc (0001567892) (Issuer)

4 - Mallinckrodt plc (0001567892) (Issuer)

3 - Mallinckrodt plc (0001567892) (Issuer)

8-K - Mallinckrodt plc (0001567892) (Filer)

8-K - Mallinckrodt plc (0001567892) (Filer)

10-Q - Mallinckrodt plc (0001567892) (Filer)

8-K - Mallinckrodt plc (0001567892) (Filer)

8-K - Mallinckrodt plc (0001567892) (Filer)

8-K - Mallinckrodt plc (0001567892) (Filer)

8-K - Mallinckrodt plc (0001567892) (Filer)

10-Q - Mallinckrodt plc (0001567892) (Filer)

DEFA14A - Mallinckrodt plc (0001567892) (Filer)

DEF 14A - Mallinckrodt plc (0001567892) (Filer)

Advanced Launch of Terlivaz® with Rapid and Successful Uptake in Hospital Formulary Access and Continued Medical Community Interest Reports First Quarter Net Sales of $424.6 Million; Net Loss of $249.3 Million; Adjusted EBITDA of $123.5 Million; Diluted Loss Per Share of $18.93 and Adjusted Diluted Earnings Per Share of $1.68 Increased Cash on Hand to $480.0 Million and Reduced Exposure to Interest Rate Volatility Through Interest Rate Cap Agreement, Demonstrating Ongoing Focus on Disciplined Balance Sheet Management Reaffirmed 2023 Net Sales and Adjusted EBITDA Guidance Conference Call and Webcast Today at 8:30 a.m. ET DUBLIN, May 9, 2023 /PRNewswire/ -- Mallinckrodt plc (NYSE:MNK) ("Malli

DUBLIN, April 24, 2023 /PRNewswire/ -- Mallinckrodt plc (NYSE:MNK), a global specialty pharmaceutical company, today announced that it will report first quarter 2023 earnings results for the period ended March 31, 2023, on Tuesday, May 9, 2023.  A conference call for investors will begin at 8:30 a.m. ET. The call can be accessed as follows: Live Call Participant Registration (including dial-in): https://register.vevent.com/register/BIbe1f9805fe5b4490acd8359f7bdd616dAudio Only Webcast Link (live and replay):https://edge.media-server.com/mmc/p/24fqexpxAt the Mallinckrodt website

Made Solid Progress on Launch of Terlivaz® with Significant Medical Community Interest Appointed Chief Scientific Officer with Proven Record of Executing Clinical Programs and Advancing Product Development Pipelines Increased Cash on Hand to $409.5 Million, Underscoring Commitment to Strengthening Balance Sheet and Disciplined Approach to Cost Management Fiscal 2023 Guidance for Adjusted EBITDA is $510 Million to $560 Million Conference Call and Webcast Today at 8:30 a.m. ET DUBLIN, Feb. 28, 2023 /PRNewswire/ -- Mallinckrodt plc (NYSE:MNK) ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, today reported results for the fourth quarter ended December 30, 2022. 

DUBLIN, Feb. 8, 2023 /PRNewswire/ -- Mallinckrodt plc (NYSE:MNK), a global specialty pharmaceutical company, today announced that it will report fourth quarter 2022 earnings results for the period ended December 30, 2022, on Tuesday, February 28, 2023.  A conference call for investors will begin at 8:30 a.m. ET. The call can be accessed as follows: Live Call Participant Registration (including dial-in): https://register.vevent.com/register/BI6e1a95af3f634687b3c55b1ae6b4ffd8 Audio Only Webcast Link (live and replay): https://edge.media-server.com/mmc/p/mfaw2pmzAt the Mallinckro

Launched Terlivaz® Following U.S. Food and Drug Administration (FDA) Approval in September; Submitted U.S. FDA Premarket Notification Application for Next-Generation Delivery System of INOmax® Strengthened Organization with Appointment of New Executives and Directors; Ordinary Shares Commenced Trading on NYSE American in October Conference Call and Webcast Today at 8:30 a.m. ET DUBLIN, Nov. 8, 2022 /PRNewswire/ -- Mallinckrodt plc (NYSE:MNK) ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, today reported results for the third quarter ended September 30, 2022.1

DUBLIN, Jan. 12, 2023 /PRNewswire/ -- Mallinckrodt plc (NYSE:MNK) ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, today announced that Dr. Peter Richardson, B.Med.Sci., BM, BS, MRCP (UK) has been appointed Executive Vice President and Chief Scientific Officer, effective January 12, 2023. With more than 30 years of research and development experience in the pharmaceutical industry, Dr. Richardson will have executive responsibility for Mallinckrodt's branded research and development (R&D), medical affairs, safety, and regulatory affairs functions. He will serve on the Company's Executive Committee and succeeds Steven Romano, M.D., who departed Mallinckrodt in Dece

SC 13D/A - Mallinckrodt plc (0001567892) (Subject)

SC 13D/A - Mallinckrodt plc (0001567892) (Subject)

SC 13D/A - Mallinckrodt plc (0001567892) (Subject)

SC 13D/A - Mallinckrodt plc (0001567892) (Subject)

SC 13D/A - Mallinckrodt plc (0001567892) (Subject)

SC 13D/A - Mallinckrodt plc (0001567892) (Subject)

SC 13D/A - Mallinckrodt plc (0001567892) (Subject)

SC 13D - Mallinckrodt plc (0001567892) (Subject)